12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

DaunoXome daunorubicin regulatory update

The European Commission granted Orphan Drug designation for liposomal daunorubicin to treat acute myelogenous leukemia (AML). Galen has...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >